• Appropriate randomisation and blinding have been used.
• The study makes use of several different types of clinical assessment methods.
• However, the sample size is relatively small, but nevertheless should be sufficient, bearing in mind that little is known about the effectiveness of cognitive behavioural therapy for mental health problems amongst adults with autistic spectrum disorders. 
• Background
Anxiety related symptomology is commonly found in those with autistic spectrum disorders (ASDs) 1 2-4 . Prevalence studies indicate that around 13.6% of children with Asperger syndrome (AS) suffer from clinically relevant anxiety 5 and up to 45% of adolescents with AS have significant difficulties with generalised anxiety, social anxiety or specific phobias 6 . A more recent study found that in a sample of young adults with AS, around 50% had an anxiety disorder 7 , while other evidence suggests that people with ASDs are likely to develop difficulties across a range of anxiety disorders (e.g. panic disorder and generalised anxiety disorder) 8 9 .
Recent guidance creates standards for the diagnosis and management of adults with ASDs 10 , and while there are an increasing number of adults being diagnosed with ASDs, the National Health Service (NHS) in the United Kingdom is charged with meeting the mental health needs of this population. Although currently there are no known data relating to the cost of AS and anxiety for the United Kingdom, the lifetime cost of ASDs is thought to be in the region of £2.4 million per person, with total cost to UK society exceeding £1 billion per year 11 . The weekly societal cost of providing care to a person with ASD in 1999-2000 was estimated to be in the region of £855.00, with an associated parental loss of income estimated to be in the region of £275.00 per week 12 . In view of this, effective treatments for anxiety in this population may lead to significant improvements in psychosocial functioning, independence and quality of life.
Cognitive behavioural therapy (CBT) has been shown to be an effective treatment for anxiety in people without ASDs e.g. 13 14 . As a consequence, there is a growing interest in examining the utility of CBT for people with ASDs who experience difficulties with anxiety. Adapted CBT has been shown to be successful at treating anxiety disorders amongst children with ASD [15] [16] [17] [18] [19] . Cardaciotto 20 and Weiss & Lunsky 21 undertook some case study work, suggesting that CBT may be helpful for adults with AS. In a recent randomised controlled trial (RCT), mindfulness-based therapy was found to reduce anxiety symptoms in adults with ASD, although it is unclear whether or not the assessors were blind within this study 22 . At present, there appear to be no published randomised single-blind control trials investigating the effectiveness of group CBT for adults with ASD and anxiety disorders.
The government autism strategy, 'Fulfilling and rewarding lives', recognises that children and adults with ASD are excluded from many NHS services, including mental health care 23 . The current study aims to help achieve the goals set within this strategy by contributing to the creation of a knowledge base. This will help inform clinical practice and service delivery for the treatment of adults with AS who experience problems with anxiety. In line with recommendations made by the National Institute for Health and Care Excellence NICE, 10 , it will also examine whether CBT is cost-effective for the treatment of anxiety amongst adults with ASD. Roberge et al. 24 argue that group CBT is more cost effective than individual CBT in patients with some types of anxiety disorders and a similar approach has been adopted within the current study.
The key aims are (a) To develop a modified, group-based CBT intervention manual for adults with AS and clinical problems with anxiety, (b) to asssess the efficacy of the CBT intervention through a pilot, single-blind, cross-over RCT with adults with AS experiencing problems with anxiety. and (c) to estimate the cost-effectiveness of the CBT intervention 
Method

Design and Randomisation
This study is a single-blind randomised cross-over trial. Due to the nature of the intervention, therapists and participants cannot be blind to treatment allocation. However researchers who carry out the assessments will be blinded in order to minimise bias. Participants will be allocated to the treatment arm (group CBT) or the waiting-list control arm using block randomisation with even pairs. The randomisation will be stratified by study site. The therapists at each research site will contact participants to inform them of their group allocation, while blind researchers will complete the assessments with participants. All of the randomisation procedures are to be completed by the Norfolk and Norwich University Hospitals NHS Foundation Trust Clinical Research and Trials Unit based at the University of East Anglia.
After 24 weeks of treatment, the two arms will cross-over and those within the waiting-list control group will receive 24 weeks of treatment, while those who have already had treatment will be assessed again following this second period of treatment. This will allow for a six month follow-up of 50% of the participants within the trial.
Allocation concealment.
Adequate allocation concealment will be ensured using an on-site computer system with allocations kept in a locked, unreadable computer file. Only the therapists will access this after enrolled participants have been entered into the computer system.
Implementation. Participants will go through a screening process conducted by researchers. This will ensure that they meet the inclusion criteria before they are enrolled into the study. Randomisation will be computer-generated. The software written to enable randomisation will use a programming system called VB.NET/ASP.NETand the underlying database will be SQL Server 2005.
Blinding. At least three researchers will be blind to the randomisation process and group allocation. They will remain blind during post-group and follow-up assessments. Participants will be regularly reminded not to disclose their group allocation to these researchers throughout their involvement in the study. All participants and the therapists will be aware of group allocation.
Participants
Thirty-six individuals will be recruited throughout Kent, South East London and Norfolk within the United Kingdom. Recruitment will be through learning disability teams, Asperger/Autism teams, AS user groups, such as Asperger East Anglia, the Kent Autistic Trust, Bridging the Gap, the Disability and Dyslexia Support Services at the University of Kent, and adult mental health teams.
The inclusion criteria are: i) participants fulfil diagnostic criteria for AS, high functioning autism (HFA) or pervasive developmental disorder -not specified (PDD-NS), ii) participants have clinical significant difficulties with anxiety as confirmed through the use the Hamilton Rating Scale for Anxiety; score of >14 qualifies inclusion, iii) participants are between 16-65 years of age, iv) Full Scale IQ >70. The exclusion criteria are: i) participants suffering from post-traumatic stress disorder, or anxiety related to substance misuse, ii) comorbid severe psychiatric disorders that impair capacity to consent to take part (e.g. psychosis), iii) current substance abuse such as alcohol or drugs.
Sample size. Bearing in mind that this is a pilot study, and considering that this study will not be a definitive RCT concerning the clinical effectiveness of this intervention, a sample size of 36 has been chosen. If we take the Hamilton Anxiety Rating Scale (HAM-A) as our primary outcome measure, and consider that other trials of CBT for anxiety disorder have reported between a 66 to 72% change on this measure as a consequence of psychological treatment [25] [26] [27] , then our study is likely to have a large effect size. However, we do not know whether the clinical effectiveness of group CBT is similar for people with AS. Once this study is completed, we will be able to estimate the sample size needed for a definitive trial.
Ethical considerations
A favourable ethical opinion was obtained from the Cambridgeshire 4 NHS Research Ethics Committee (Reference: 10/H0305/42). Informed consent will be sought from participants and their carers. Participants may withdraw from the trial at any stage without giving a reason. The withdrawal will not affect access to other treatments or services. All information disclosed and data collected in the study will be confidential, and individuals will not be identifiable in any published material. In line with Standard Operating Procedures the reporting of Serious Adverse Events will be made to the Chief Investigator, who together with the study sponsor (Norfolk and Suffolk NHS Foundation Trust), will follow national procedures for reporting such incidents to the NHS ethics committee.
Intervention
The intervention used within this study comprises 24 weekly sessions, each lasting approximately one hour. Those in the treatment arm will receive 3 initial sessions of 1:1 CBT, followed by 21 group CBT sessions. The initial three sessions of therapy aim to help socialise each participant into cognitive behavioural therapy and to address any concerns they may have about joining the group.
The treatment manual 28 includes the following topics (a) cognitive restructuring, (b) anxiety management techniques, (c) systematic desensitization, (d) exposure to feared social situations, and (e) social skills training. Cognitive restructuring refers to the process of learning to identify unhelpful cognitions which may trigger or maintain anxiety and then learning to challenge or replace these cognitions with more appropriate appraisals. Anxiety management techniques refer to progressive relaxation training, learning to identify anxietyrelated triggers, and the development of appropriate techniques to successfully manage anxiety. Systematic desensitisation and exposure to feared social situations involve the gradual exposure of the participant in a safe manner to social situations that provoke fear. These techniques allow participants to learn that anxiety is not harmful and help to reduce avoidance to feared situations. Finally, social skills training refers to the actual teaching of social skills including how to understand verbal and non-verbal social cues, and appropriate social interaction across contexts. These skills will be practiced in vivo. All sessions will be co-facilitated by registered clinical psychologists or trained cognitive-behaviour therapists. All outcome measures will be administered by the researchers at baseline (prior to any treatment), after week 24 (Follow-up One) and after week 52 (Follow-up Two). Besides the primary and secondary measures at baseline we will record individual demographics background, which includes their age, gender, ethnic group, diagnostic history, current medication and any prior treatment.
Outcome Measures and Analysis
Primary Outcome Measures Social Phobia Inventory
29
. This is a 17-item self-report measure of behavioural, physiological and cognitive symptoms associated with social phobia. Participants rate the frequency with which they experience each symptom over the last week, using a five-point Likert-type scale (0-4).
Liebowitz Social Anxiety Scale
30
. This instrument is a self-report scale that assesses fear and avoidance throughout 24 listed situations, which are likely to elicit social anxiety.
Hamilton Rating Scale for Anxiety
31
. This is a structured clinician rated scale incorporating 14 factors which are considered valid indicators of anxiety. Each factor reflects a symptom of anxiety; physical as well as mental symptoms are represented. The factors are scored on a 5-point scale as part of a structured interview.
Secondary outcome measures
Social and Emotional Functioning Interview (Informant and Subject Versions) 32 . A semi-structured clinician rated assessment of everyday social and psychiatric functioning that was designed to assess independence, leisure, interpersonal problems, employment, and social relationships. Some items are shared with the Autistic Diagnostic Observation Schedule. 33 34 . A self-report 20-item measure of anxiety as experienced in social situations associated with social anxiety and social phobia in accordance to the DSM-IV criteria. Experiences are rated on a 5-point scale from 0 (not at all characteristic of me) to 4 (extremely characteristic of me).
Social Interaction Anxiety Scale
Fear Questionnaire
35
. A self-report questionnaire regarding the individual perception of fears and phobias; respondents are asked how likely they avoid each of the listed situations, due to anxiety/fear or any other unpleasant feelings. In addition to the 15 pre-existing items the individual is asked to document and score any individual phobias they would wish treated.
Hamilton Rating Scale for Depression
36
. This structured clinician rated interview is considered a valid indicator of depression and the ratings are based on the interviewer's objective and subjective perceptions during the assessment. Eight items are scored on a 0 (not present) to 4 (severe) point scale, and nine items are scored from 0-2 (levels of severity).
SF-36 (www.sf-36.org) and EQ-5D (www.euroqol.org). These two self-report instruments will be used to assess overall health related quality of life (HRQoL). Summary scores from the SF-36 and EQ-5D questionnaires will be used to estimate both health profiles and an index of overall HRQoL (utility) using standard algorithms relevant to the UK population. 37 38 Resource Use and Cost. Health service use, patient out of pocket costs and the value of any lost productivity to society will be collected using an adapted version of the client . Where national estimates are not available, attempts will be made to obtain representative local or regional unit costs. A common price year will be used throughout to be determined at the point of analysis. As the follow-up period for this trial is less than one year, discounting of costs or outcomes is not necessary.
Statistical methods
Data will be analysed using repeated measures statistics (e.g. repeated measures ANOVA and ANCOVA) making use of intent-to-treat analysis as appropriate. We may wish to control for various variables in this analysis, for example differences in baseline anxiety scores. Summary scores from the SF-36 and EQ-5D questionnaires will be used to estimate both health profiles and an index of overall health related quality of life (utility). SF-36 and EQ-5D results will be converted to utilities using the SF-6D 37 and MVH 38 algorithms respectively. Quality Adjusted Life Years (QALYs) gained will be estimated from the resulting area under the curves.
Collection of both SF-36 and EQ-5D will allow comparison of performance of the two instruments in this pilot study to inform data collection tools for future full trials. Costs will be analysed from the perspectives of the public sector (NHS and social services) and society, and based on resource use gleaned from the resource use questionnaire multiplied by unit costs as described above.
Within-trial economic analyses will report mean cost and outcome, incremental cost and outcome and incremental cost effectiveness ratios over a time horizon of 24 weeks (that is, comparing approximately six months of group CBT versus six months of 'treatment as usual'). Outcomes in the economic analysis will be Social and Emotional Functioning Interview score and QALYs gained (estimated using both the EQ-5D and SF-6D algorithms). Uncertainty around the point estimate of the ICER will be presented as a cost-effectiveness acceptability curve 41 . Additional modelling analyses will extend the time horizon to five years based on extrapolation of trial costs and outcomes to the longer time horizon (and making use of the 24 week follow-up data in the intervention arm). Different assumptions as to the duration of effectiveness of treatment will be compared in a series of scenario analyses.
Discussion
Recently published NICE guidelines 10 call for greater support and service planning for those with ASDs. Despite the high prevalence of anxiety in this population, there are few studies investigating appropriate intervention. This study aims to invetigate the efficacy of CBT for anxiety in adults with ASDs. This study will involve developing and trialling modified group CBT specifically for adults with ASDs experiencing problems with anxiety. The use of CBT may lead to a reduction in anxiety and an increase in social and occupational functioning amongst adults with ASDs. The study will also investigate whether the use of group CBT is a cost effective approach to treating anxiety in this population. This is not a definitive trial, and although we aim to determine whether or not CBT is likely to be effective, once treatement is completed, participants will be invited to take part in further interviews in order to ascertain their personal views about the intervention.
Trial Status
The trial is currently closed to recruitment, and all sites have crossed over. Data collection is scheduled to finish in January 2014.
Trial Registration
ISRCTN 30265294 (DOI: 10.1186/ISRCTN30265294), UKCRN 8370
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• The aims of this trial are to (a) develop group-based cognitve behavioural therapy for people with Asperger syndrome and high functioning autism who have anxiety disorders, (b) to asssess the efficacy of the intervention through a pilot, single-blind, cross-over randomised control trial, and (c) to estimate the cost-effectiveness of the CBT intervention compared to no intervention.
Key Messages
• This study is a pilot trial which will determine whether or not group cognitive behavioural therapy is likely to be an effective intervention for anxiety disorders amongst people who have austistic spectrum disorders.
• The trial will also determine whether the intervention is cost effective.
• The study will also examine the views participants have about the intervention.
Strengths and Limitations
Background
Recent guidance creates standards for the diagnosis and management of adults with ASDs 10 , and while there are an increasing number of adults being diagnosed with ASDs, the National Health Service (NHS) in the United Kingdom is charged with meeting the mental health needs of this population. Although currently there are no known data relating to the cost of AS and anxiety for the United Kingdom, the lifetime cost of ASDs is thought to be in the region of £2.4 million per person, with total cost to UK society exceeding £1 billion per year 11 . The weekly societal cost of providing care to a person with an ASD in 1999-2000 was estimated to be in the region of £855.00, with an associated parental loss of income estimated to be in the region of £275.00 per week 12 . In view of this, effective treatments for anxiety in this population may lead to significant improvements in psychosocial functioning, independence and quality of life.
Cognitive behavioural therapy (CBT) has been shown to be an effective treatment for anxiety in people without ASDs 13 14 . As a consequence, there is a growing interest in examining the utility of CBT for people with ASDs who experience difficulties with anxiety. Adapted CBT has been shown to be successful at treating anxiety disorders amongst children with ASD [15] [16] [17] [18] [19] . Cardaciotto 20 and Weiss & Lunsky 21 undertook some case study work, suggesting that CBT may be helpful for adults with AS. In a recent randomised controlled trial (RCT), mindfulness-based therapy was found to reduce anxiety symptoms in adults with ASD, although it is unclear whether or not the assessors were blind within this study 22 . At present, there appears to be no published randomised single-blind control trials investigating the effectiveness of group CBT for adults with ASD and anxiety disorders.
The government autism strategy, 'Fulfilling and rewarding lives', recognises that children and adults with ASD are excluded from many NHS services, including mental health care 23 . The current study aims to help achieve the goals set within this strategy by contributing to the creation of a knowledge base. This will help inform clinical practice and service delivery for the treatment of adults with AS who experience problems with anxiety. In line with recommendations made by the National Institute for Health and Care Excellence NICE, 10 , it will also examine whether CBT is cost-effective for the treatment of anxiety amongst adults with ASD. Roberge et al. 24 argue that group CBT is more cost effective than individual CBT in patients with some types of anxiety disorders and a similar approach has been adopted within the current study. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Method
Design and Randomisation
This study is a single-blind randomised cross-over trial. Due to the nature of the intervention, therapists and participants cannot be blind to treatment allocation. However researchers who carry out the assessments will be blinded in order to minimise bias. Participants will be allocated to the treatment arm (group CBT) or the waiting-list control arm using block randomisation with even pairs. The randomisation will be stratified by study site. The therapists at each research site will contact participants to inform them of their group allocation, while blinded researchers will complete the assessments with participants. All of the randomisation procedures are to be completed by the Norfolk and Norwich University Hospitals NHS Foundation Trust Clinical Research and Trials Unit based at the University of East Anglia.
Allocation concealment.
Participants
Ethical considerations
A favourable ethical opinion was obtained from the Cambridgeshire 4 NHS Research Ethics Committee (Reference: 10/H0305/42). Informed consent will be sought from participants and their carers. Research workers are responsible for providing study information to participants and obtaining consent; all participants are afforded time to consider whether they wish to participate and are given the opportunity to ask any questions. Information about the study was provided in an "easier to read" format for participants who may have reading difficulties. Participants may withdraw from the trial at any stage without giving a reason. The withdrawal will not affect access to other treatments or services. Participants will have the contact details of the study team and are able to make contact and ask any questions. Should they wish to do so, participants who withdraw from the trial are able to complete the scheduled outcome assessments. All information disclosed and data collected in the study will be confidential, and individuals will not be identifiable in any published material. In line with Standard Operating Procedures the reporting of Serious Adverse Events will be made to the Chief Investigator, who together with the study sponsor (Norfolk and Suffolk NHS Foundation Trust), will follow national procedures for reporting such incidents to the NHS ethics committee.
Intervention
In order to ensure adherence to treatment, a treatment manual 28 was developed with specific aims for each session, and all sessions will be delivered by a registered clinical psychologist or a qualified cognitive-behavioural therapist. The treatment manual includes the following topics (a) cognitive restructuring, (b) anxiety management techniques, (c) systematic desensitization, (d) exposure to feared social situations, and (e) social skills training. Cognitive restructuring refers to the process of learning to identify unhelpful cognitions which may trigger or maintain anxiety and then learning to challenge or replace these cognitions with more appropriate appraisals. Anxiety management techniques refer to progressive relaxation training, learning to identify anxiety-related triggers, and the development of appropriate techniques to successfully manage anxiety. Systematic desensitisation and exposure to feared social situations involve the gradual exposure of the participant in a safe manner to social situations that provoke fear. These techniques allow participants to learn that anxiety is not harmful and help to reduce avoidance to feared situations. Finally, social skills training refers to the actual teaching of social skills including how to understand verbal and non-verbal social cues, and appropriate social interaction across contexts. These skills will be practiced in vivo. In addition to the intervention, participants in both arms before and after cross-over were permitted to engage in treatmentas-usual (TAU).
Outcome Measures and Analysis
All outcome measures will be administered by the researchers at baseline (prior to any treatment), after week 24 (Follow-up One) and after week 52 (Follow-up Two). Besides the primary and secondary measures at baseline we will record individual demographics background, which includes their age, gender, ethnic group, diagnostic history, current medication and any prior treatment.
Primary Outcome Measures Social Phobia Inventory
29
Liebowitz Social Anxiety Scale
30
Hamilton Rating Scale for Anxiety
31
. This is a structured clinician rated scale incorporating 14 factors which are considered valid indicators of anxiety. Each factor reflects a symptom of anxiety; physical as well as mental symptoms are represented. The factors are scored on a 5-point scale as part of a structured interview. 32 . A semi-structured clinician rated assessment of everyday social and psychiatric functioning that was designed to assess independence, leisure, interpersonal problems, employment, and social relationships. Some items are shared with the Autistic Diagnostic Observation Schedule. 33 34 . A self-report 20-item measure of anxiety as experienced in social situations associated with social anxiety and social phobia in accordance to the DSM-IV criteria. Experiences are rated on a 5-point scale from 0 (not at all characteristic of me) to 4 (extremely characteristic of me).
Secondary outcome measures
Social and Emotional Functioning Interview (Informant and Subject Versions)
Social Interaction Anxiety Scale
Fear Questionnaire
35
. A self-report questionnaire regarding the individual perception of fears and phobias; respondents are asked how likely they avoid each of the listed situations, due to anxiety/fear or any other unpleasant feelings. In addition to the 15 pre-existing items the individual is asked to document and score any individual phobias they would wish treated. . This structured clinician rated interview is considered a valid indicator of depression and the ratings are based on the interviewer's objective and subjective perceptions during the assessment. Eight items are scored on a 0 (not present) to 4 (severe) point scale, and nine items are scored from 0-2 (levels of severity).
SF-36 (www.sf-36.org) and EQ-5D (www.euroqol.org).
These two self-report instruments will be used to assess overall health related quality of life (HRQoL). Summary scores from the SF-36 and EQ-5D questionnaires will be used to estimate both health profiles and an index of overall HRQoL (utility) using standard algorithms relevant to the UK population. 37 38 Resource Use and Cost. Health service use, patient out of pocket costs and the value of any lost productivity to society will be collected using an adapted version of the client service receipt inventory . This is a tool specifically designed to measure patient resource use in the area of mental health, although has subsequently been adapted to other areas too. Resource use involved in delivering the intervention (i.e. conducting the group based sessions) will be based on time records for professionals and participants. Resource use estimates will be multiplied by unit costs of services extracted from standard NHS sources (e.g. Unit Costs of Health and Social Care 39 , National Schedule of Reference Costs 40 ). Where national estimates are not available, attempts will be made to obtain representative local or regional unit costs. A common price year will be used throughout to be determined at the point of analysis. As the follow-up period for this trial is less than one year, discounting of costs or outcomes is not necessary.
Statistical methods
Within-trial economic analyses will report mean cost and outcome, incremental cost and outcome and incremental cost effectiveness ratios over a time horizon of 24 weeks (that is, comparing approximately six months of group CBT versus six months of 'treatment as usual'). Outcomes in the economic analysis will be Social and Emotional Functioning Interview score and QALYs gained (estimated using both the EQ-5D and SF-6D algorithms). Uncertainty around the point estimate of the ICER will be presented as a cost-effectiveness acceptability curve 41 . Additional modelling analyses will extend the time horizon to five years based on extrapolation of trial costs and outcomes to the longer time horizon (and making use of the 24 week follow-up data in the intervention arm). Different assumptions as to the duration of effectiveness of treatment will be compared in a series of scenario analyses. 
Discussion
Trial Status
The trial is currently closed to recruitment, and all sites have crossed over. Data collection is scheduled to finish in January 2014. • People with autistic spectrum disorders have higher rates of mental health problems than the general population.
• The aims of this trial are to (a) develop a group-based cognitve behavioural therapy for people with Asperger syndrome and high functioning autism who have anxiety disorders, (b) to asssess the efficacy of the intervention through a pilot, single-blind, cross-over randomised control trial, and (c) to estimate the cost-effectiveness of the CBT intervention compared to no intervention.
Key Messages
Strengths and Limitations
Background
Method
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Allocation concealment.
Participants
Ethical considerations
Intervention
In order to ensure adherence to treatment, a treatment manual 28 was developed with specific aims for each session, and all sessions will be delivered by a registered clinical psychologist or a qualified cognitive-behavioural therapist. The treatment manual includes the following topics (a) cognitive restructuring, (b) anxiety management techniques, (c) systematic desensitization, (d) exposure to feared social situations, and (e) social skills training. Cognitive restructuring refers to the process of learning to identify unhelpful cognitions which may trigger or maintain anxiety and then learning to challenge or replace these cognitions with more appropriate appraisals. Anxiety management techniques refer to progressive relaxation training, learning to identify anxiety-related triggers, and the development of appropriate techniques to successfully manage anxiety. Systematic desensitisation and exposure to feared social situations involve the gradual exposure of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y participant in a safe manner to social situations that provoke fear. These techniques allow participants to learn that anxiety is not harmful and help to reduce avoidance to feared situations. Finally, social skills training refers to the actual teaching of social skills including how to understand verbal and non-verbal social cues, and appropriate social interaction across contexts. These skills will be practiced in vivo. All sessions will be co-facilitated by registered clinical psychologists or trained cognitive-behaviour therapists. In addition to the intervention, participants in both arms before and after cross-over were permitted to engage in treatment-as-usual (TAU).
Outcome Measures and Analysis
Primary Outcome Measures Social Phobia Inventory
29
Liebowitz Social Anxiety Scale
30
Hamilton Rating Scale for Anxiety
31
Secondary outcome measures
Social Interaction Anxiety Scale
Fear Questionnaire
35
. A self-report questionnaire regarding the individual perception of fears and phobias; respondents are asked how likely they avoid each of the listed situations, due to anxiety/fear or any other unpleasant feelings. In addition to the 15 pre-existing items the individual is asked to document and score any individual phobias they would wish treated. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 36 . This structured clinician rated interview is considered a valid indicator of depression and the ratings are based on the interviewer's objective and subjective perceptions during the assessment. Eight items are scored on a 0 (not present) to 4 (severe) point scale, and nine items are scored from 0-2 (levels of severity).
SF-36 (www.sf-36.org) and EQ-5D (www.euroqol.org). These two self-report instruments will be used to assess overall health related quality of life (HRQoL). Summary scores from the SF-36 and EQ-5D questionnaires will be used to estimate both health profiles and an index of overall HRQoL (utility) using standard algorithms relevant to the UK population. 37 38 Resource Use and Cost. Health service use, patient out of pocket costs and the value of any lost productivity to society will be collected using an adapted version of the client service receipt inventory . This is a tool specifically designed to measure patient resource use in the area of mental health, although has subsequently been adapted to other areas too. Resource use involved in delivering the intervention (i.e. conducting the group based sessions) will be based on time records for professionals and participants. Resource use estimates will be multiplied by unit costs of services extracted from standard NHS sources (e.g. Unit Costs of Health and Social Care 39 , National Schedule of Reference Costs 40 ). Where national estimates are not available, attempts will be made to obtain representative local or regional unit costs. A common price year will be used throughout to be determined at the point of analysis. As the follow-up period for this trial is less than one year, discounting of costs or outcomes is not necessary.
Statistical methods
Within-trial economic analyses will report mean cost and outcome, incremental cost and outcome and incremental cost effectiveness ratios over a time horizon of 24 weeks (that is, comparing approximately six months of group CBT versus six months of 'treatment as usual'). Outcomes in the economic analysis will be Social and Emotional Functioning Interview score and QALYs gained (estimated using both the EQ-5D and SF-6D algorithms). Uncertainty around the point estimate of the ICER will be presented as a cost-effectiveness acceptability curve 41 . Additional modelling analyses will extend the time horizon to five years based on extrapolation of trial costs and outcomes to the longer time horizon (and making use of the 24 week follow-up data in the intervention arm). Different assumptions as to the duration of effectiveness of treatment will be compared in a series of scenario analyses. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 10 call for greater support and service planning for those with ASDs. Despite the high prevalence of anxiety in this population, there are few studies investigating appropriate intervention. This study aims to invetigate the efficacy of CBT for anxiety in adults with ASDs. This study will involve developing and trialling modified group CBT specifically for adults with ASDs experiencing problems with anxiety. The use of CBT may lead to a reduction in anxiety and an increase in social and occupational functioning amongst adults with ASDs. The study will also investigate whether the use of group CBT is a cost effective approach to treating anxiety in this population. This is not a definitive trial, and although we aim to determine whether or not CBT is likely to be effective, once treatement is completed, participants will be invited to take part in further interviews in order to ascertain their personal views about the intervention.
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